Plant Name: Teucrium lanigerum
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPBAR1; ADRA2C; ADRA2A; | |
| NMUR2; | |
| PTPN1; PTPN2; ACP1; PTPRF; | |
| ALPI; RECQL; HSD11B1; AKR1B10; AKR1B1; POLB; | |
| GAA; ACHE; | |
| MAPK1; MAP2K1; PRKCA; | |
| CA2; CA12; CA7; CA4; | |
| RORC; | |
| NR1H4; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP2C19; |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | Q02750 | CHEMBL3587 |
| Protein Kinase | PRKCA | Protein kinase C alpha | P17252 | CHEMBL299 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
| Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.484E-09 | 7.587E-05 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.475E-07 | 1.071E-03 | CA12, CA2, CA4, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.375E-07 | 1.470E-03 | CA12, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 6.496E-07 | 1.768E-03 | ALPI, CA12, CA2, CA4, CA7, NR1H4, PRKCA, PTPN1, RORC |
| BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 2.312E-06 | 3.873E-03 | ADRA2A, AKR1B1, CA12, CA2, CA7, MAPK1, NMUR2, NR1H4, PTPN2 |
| BP | GO:0065007; biological regulation | GO:0010817; regulation of hormone levels | 3.605E-06 | 4.339E-03 | ACHE, ADRA2A, ADRA2C, AKR1B1, HSD11B1, NR1H4, PRKCA |
| CC | GO:0016020; membrane | GO:0005886; plasma membrane | 4.221E-06 | 4.339E-03 | ACHE, ACP1, ADRA2A, ADRA2C, ALPI, CA12, CA2, CA4, GAA, GPBAR1, MAP2K1, MAPK1, NMUR2, PRKCA, PTPN1, PTPN2, PTPRF |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 5.222E-06 | 4.374E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 5.222E-06 | 4.374E-03 | GPBAR1, NR1H4 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 5.222E-06 | 4.374E-03 | ADRA2A, ADRA2C |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 5.222E-06 | 4.374E-03 | GPBAR1, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0035335; peptidyl-tyrosine dephosphorylation | 8.900E-06 | 6.683E-03 | ACP1, PTPN1, PTPN2, PTPRF |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 1.044E-05 | 6.684E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 1.044E-05 | 6.684E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0090170; regulation of Golgi inheritance | 1.044E-05 | 6.684E-03 | MAP2K1, MAPK1 |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 1.044E-05 | 6.684E-03 | PTPN1, PTPN2 |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 1.351E-05 | 8.407E-03 | ADRA2A, ADRA2C, MAPK1, PRKCA |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.734E-05 | 9.703E-03 | AKR1B1, AKR1B10, CYP2C19, HSD11B1, NR1H4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 5.278E-09 | 7.072E-07 | CA12; CA2; CA4; CA7 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 2.427E-06 | 1.626E-04 | PTPN1; MAPK1; ACP1; PTPRF |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.223E-05 | 3.395E-04 | ACHE; MAP2K1; MAPK1; PRKCA |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.267E-05 | 3.395E-04 | MAP2K1; MAPK1; PRKCA; CYP2C19 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 5.165E-05 | 8.947E-04 | MAP2K1; MAPK1; PRKCA |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 7.736E-06 | 3.395E-04 | AKR1B10; GAA; AKR1B1 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 2.966E-05 | 6.624E-04 | PTPN1; MAP2K1; MAPK1; PTPRF |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 6.074E-05 | 8.947E-04 | MAP2K1; MAPK1; ADRA2C; ADRA2A |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 8.075E-05 | 9.439E-04 | MAP2K1; MAPK1; PRKCA |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 6.677E-05 | 8.947E-04 | MAP2K1; MAPK1; PRKCA |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 6.354E-05 | 8.947E-04 | MAP2K1; MAPK1; PRKCA |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 9.241E-05 | 9.526E-04 | MAP2K1; MAPK1; PRKCA |
| hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 8.453E-05 | 9.439E-04 | MAP2K1; MAPK1; PRKCA |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.923E-04 | 1.777E-03 | MAP2K1; MAPK1; PRKCA |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 2.196E-04 | 1.839E-03 | MAP2K1; MAPK1; PRKCA |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 2.901E-04 | 2.106E-03 | MAP2K1; MAPK1; PRKCA |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 1.989E-04 | 1.777E-03 | MAP2K1; MAPK1; PRKCA |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 2.342E-04 | 1.846E-03 | MAP2K1; MAPK1; PRKCA |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 2.987E-04 | 2.106E-03 | MAP2K1; MAPK1; PRKCA |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 3.164E-04 | 2.120E-03 | MAP2K1; MAPK1; PRKCA |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 4.714E-04 | 2.765E-03 | MAP2K1; MAPK1; PRKCA |
| hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 4.952E-04 | 2.765E-03 | MAP2K1; MAPK1; PRKCA |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 4.952E-04 | 2.765E-03 | MAP2K1; MAPK1; PRKCA |
| hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 6.980E-04 | 3.464E-03 | MAP2K1; MAPK1; PRKCA |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 8.760E-04 | 3.913E-03 | MAP2K1; MAPK1; PRKCA |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 8.417E-04 | 3.889E-03 | MAP2K1; MAPK1; PRKCA |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.101E-03 | 4.469E-03 | MAP2K1; MAPK1; PRKCA |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.476E-03 | 5.496E-03 | MAP2K1; MAPK1; PRKCA |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 2.255E-03 | 7.748E-03 | MAP2K1; MAPK1; PRKCA |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 2.224E-03 | 7.748E-03 | MAP2K1; MAPK1; PRKCA |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 2.516E-03 | 8.225E-03 | MAP2K1; MAPK1; PRKCA |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 3.094E-03 | 9.213E-03 | MAP2K1; MAPK1; PRKCA |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 4.398E-03 | 1.052E-02 | HSD11B1; AKR1B10; GAA; AKR1B1; ALPI; CYP2C19 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 4.288E-03 | 1.045E-02 | MAP2K1; MAPK1; PRKCA |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 2.070E-03 | 7.498E-03 | MAP2K1; MAPK1 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 5.398E-03 | 1.247E-02 | NMUR2; ADRA2C; ADRA2A |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 2.482E-03 | 8.225E-03 | MAP2K1; MAPK1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 6.546E-03 | 1.462E-02 | MAP2K1; MAPK1; PRKCA |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 6.457E-04 | 3.328E-03 | MAP2K1; MAPK1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 2.746E-03 | 8.558E-03 | MAPK1; PRKCA |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 3.312E-03 | 9.443E-03 | MAP2K1; MAPK1 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 2.929E-03 | 8.921E-03 | MAP2K1; MAPK1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 3.822E-03 | 1.020E-02 | MAP2K1; MAPK1 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 2.657E-03 | 8.476E-03 | AKR1B10; AKR1B1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 3.928E-03 | 1.020E-02 | MAP2K1; MAPK1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 3.312E-03 | 9.443E-03 | MAP2K1; MAPK1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 4.035E-03 | 1.020E-02 | MAP2K1; MAPK1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 3.411E-03 | 9.523E-03 | MAP2K1; MAPK1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 4.035E-03 | 1.020E-02 | MAP2K1; MAPK1 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 5.591E-04 | 2.997E-03 | MAP2K1; MAPK1 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 9.553E-03 | 1.782E-02 | MAP2K1; MAPK1; PRKCA |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.292E-03 | 4.945E-03 | MAP2K1; MAPK1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 5.937E-03 | 1.348E-02 | MAP2K1; MAPK1 |
| hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 4.144E-03 | 1.028E-02 | CA2; PRKCA |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 7.154E-03 | 1.522E-02 | MAP2K1; MAPK1 |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 1.169E-03 | 4.608E-03 | MAPK1; PRKCA |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 7.583E-03 | 1.540E-02 | MAPK1; PRKCA |
| hsa04713 | Circadian entrainment_Homo sapiens_hsa04713 | 6.737E-03 | 1.480E-02 | MAPK1; PRKCA |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 4.043E-04 | 2.580E-03 | CA2; CA4 |
| hsa05020 | Prion diseases_Homo sapiens_hsa05020 | 9.417E-04 | 4.071E-03 | MAP2K1; MAPK1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 7.296E-03 | 1.528E-02 | MAP2K1; MAPK1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 3.822E-03 | 1.020E-02 | CA2; NR1H4 |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 7.583E-03 | 1.540E-02 | MAPK1; PRKCA |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 8.324E-03 | 1.640E-02 | MAP2K1; MAPK1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 8.783E-03 | 1.706E-02 | PTPN1; PTPRF |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 8.938E-03 | 1.711E-02 | MAP2K1; MAPK1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 8.024E-03 | 1.605E-02 | MAP2K1; MAPK1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.439E-02 | 2.468E-02 | MAP2K1; MAPK1; PRKCA |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 6.875E-03 | 1.486E-02 | CA2; PRKCA |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 5.063E-03 | 1.190E-02 | HSD11B1; CYP2C19 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.417E-02 | 2.465E-02 | MAP2K1; MAPK1 |
| hsa04724 | Glutamatergic synapse_Homo sapiens_hsa04724 | 9.573E-03 | 1.782E-02 | MAPK1; PRKCA |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.056E-02 | 1.939E-02 | MAP2K1; MAPK1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.267E-02 | 2.263E-02 | MAP2K1; MAPK1 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 1.107E-02 | 2.005E-02 | MAP2K1; MAPK1 |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 1.285E-02 | 2.266E-02 | MAP2K1; MAPK1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 7.869E-04 | 3.766E-03 | AKR1B10; AKR1B1 |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 1.574E-02 | 2.636E-02 | MAPK1; PRKCA |
| hsa05034 | Alcoholism_Homo sapiens_hsa05034 | 2.249E-02 | 3.675E-02 | MAP2K1; MAPK1 |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 1.455E-02 | 2.468E-02 | MAP2K1; MAPK1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 2.892E-02 | 4.558E-02 | POLB; MAPK1 |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 3.129E-02 | 4.876E-02 | MAP2K1; MAPK1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 2.737E-02 | 4.367E-02 | MAP2K1; MAPK1 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 2.439E-02 | 3.938E-02 | MAP2K1; MAPK1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 9.963E-04 | 4.172E-03 | AKR1B10; AKR1B1 |
| hsa00790 | Folate biosynthesis_Homo sapiens_hsa00790 | 1.805E-02 | 2.987E-02 | ALPI |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C; ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; HSD11B1; HSD11B1; AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | MAPK1; ACHE |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; ADRA2C; CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA2C; ADRA2A; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ADRA2C; ACHE; ACHE; ACHE |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; HSD11B1; ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; ADRA2C; ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1; HSD11B1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE |